Q3 FY2026 EarningsQ3 FY26 results missed consensus estimates on the bottom line: GAAP EPS was -$0.08 vs. -$0.06 expected, and Net Loss reached $1.99M compared to the $1.63M consensus. Revenue was $0, in-line with expectations as the company shifts focus from B2B sales to pharmaceutical R&D. Despite a wider loss, the company maintained a cash balance of $3.5M following recent equity raises, though management reiterated a going concern warning with liquidity sufficient only through Q1 FY27.
Financial report interval: 2026.03.03 - 2026.05.31
Overview: Lexaria Bioscience(LEXX) the Revenue is 0 (-100%), Meet estimate;the EBIT is -1.994 M (+46.84%), Miss estimate;the EPS is -1.2 (+61.9%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B100.00%
0.00B100.00%
0.00B0.00%
EBITMiss expectations
-0.00B46.84%
-0.00B56.54%
-0.00B9.70%
EPSMiss expectations
-1.261.90%
-0.971.43%
-0.30009.53%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf